全球人類肝臟模型市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計人類肝臟模型市場將從 2025 年的 21.8 億美元成長到 2034 年的 73.2 億美元，2026 年至 2034 年的複合年成長率為 14.38%。

隨著對先進臨床前試驗、藥物研發和個人化醫療的需求日益成長，全球人工肝臟模型市場正受到廣泛關注。傳統的2D培養和動物模型在模擬人類肝臟的生理功能方面存在局限性，因此人們對3D生物列印技術、晶片器官技術和幹細胞衍生肝臟模型越來越感興趣。這些技術能夠更精確地模擬藥物代謝、毒性和疾病進展，從而提高轉化研究的成功率。

製藥公司正在利用人類肝臟模型來加速藥物開發平臺，最大限度地減少臨床試驗失敗，並滿足嚴格的安全評估監管要求。研究機構正在利用晶片肝臟平台在受控環境下研究非酒精性脂肪性肝病（NAFLD）、肝炎和肝纖維化等疾病。此外，生物列印技術和可擴展培養系統的進步正在加速高可重複性肝組織的商業性化應用。

未來，人類肝臟模型、人工智慧驅動的預測分析、高通量篩檢和多器官平台的整合將重塑生物醫學研究。精準醫學的進步將使利用患者來源的肝臟模型進行個人化治療試驗成為可能，從而為客製化治療通訊協定鋪平道路。隨著生物技術、組織工程和計算生物學的融合，這個市場有望徹底改變藥物研發和疾病建模。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球人類肝臟模型市場：依產品分類

• 市場分析、洞察與預測
• 2D模型（細胞株、​​原代細胞）
• 3D模型（晶片肝臟、類器官、球狀體等）

第5章：全球人類肝臟模型市場：按應用分類

• 市場分析、洞察與預測
• ADME 測試
• 毒性測試
• 疾病建模
• 其他

第6章：全球人類肝臟模型市場：依最終用途分類

• 市場分析、洞察與預測
• 學術研究機構
• 製藥和生物技術公司
• 受託研究機構

第7章 全球人類肝臟模型市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • ATCC
  • Merck KGaA
  • AcceGen
  • ZenBio Inc
  • Organovo Holdings Inc
  • BioIVT
  • InSphero
  • Emulate Inc
  • Mimetas
  • CN Bio Innovations Ltd

The Human Liver Model Market size is expected to reach USD 7.32 Billion in 2034 from USD 2.18 Billion (2025) growing at a CAGR of 14.38% during 2026-2034.

The global human liver model market is gaining traction as demand for advanced preclinical testing, drug discovery, and personalized medicine intensifies. Traditional 2D cultures and animal models face limitations in replicating human liver physiology, driving interest in 3D bioprinted, organ-on-chip, and stem cell-derived liver models. These technologies enable more accurate simulation of drug metabolism, toxicity, and disease progression, improving translational success rates.

Pharmaceutical companies are adopting human liver models to accelerate drug pipelines, minimize clinical trial failures, and comply with stringent regulatory requirements for safety evaluation. Research institutes are leveraging liver-on-chip platforms to study conditions such as nonalcoholic fatty liver disease (NAFLD), hepatitis, and fibrosis in controlled environments. Moreover, bioprinting advances and scalable culture systems are facilitating commercial deployment of highly reproducible liver tissues.

In the future, integration of human liver models with AI-driven predictive analytics, high-throughput screening, and multi-organ platforms will reshape biomedical research. As precision medicine advances, patient-derived liver models will allow individualized therapy testing, paving the way for customized treatment protocols. With growing convergence of biotechnology, tissue engineering, and computational biology, the market is poised to revolutionize drug development and disease modeling.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• 2D Models (Cell lines, Primary Cells)
• 3D Models (Liver on Chip, Organoids, Spheroids, Others)

By Application

• ADME Studies
• Toxicology Testing
• Disease Modelling
• Others

By End Use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

COMPANIES PROFILED

• ATCC, Merck KGaA, AcceGen, ZenBio Inc, Organovo Holdings Inc, BioIVT, InSphero, Emulate Inc, Mimetas, CN Bio Innovations Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN LIVER MODEL MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. 2D Models (Cell lines, Primary Cells) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. 3D Models (Liver on Chip, Organoids, Spheroids, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN LIVER MODEL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. ADME Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Disease Modelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN LIVER MODEL MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN LIVER MODEL MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN LIVER MODEL INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ATCC
  • 9.2.2 Merck KGaA
  • 9.2.3 AcceGen
  • 9.2.4 ZenBio Inc
  • 9.2.5 Organovo Holdings Inc
  • 9.2.6 BioIVT
  • 9.2.7 InSphero
  • 9.2.8 Emulate Inc
  • 9.2.9 Mimetas
  • 9.2.10 CN Bio Innovations Ltd